Search

Displaying results 1651 - 1660 of 2420 in total
  1. Drug

    Ziftomenib

    go.drugbank.com/drugs/DB17171
    ApprovedInvestigational

    Ziftomenib is a potent and highly selective menin inhibitor. This drug was approved by the FDA on November 13th, 2025, for the treatment of relapsed or refractory acute myeloid leukemia (AML) in adults with a susceptible NPM1 mutation wh...

    Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 Substrates
  2. Drug

    Redaporfin

    go.drugbank.com/drugs/DB17219
    Investigational

    Categories: P-glycoprotein substrates
  3. Drug

    P-BCMA-101

    go.drugbank.com/drugs/DB17371
    Investigational

    P-BCMA-101 is an autologous CAR-T therapy developed using Poseida’s piggyBac platform technology.

  4. Drug

    Pirtobrutinib

    go.drugbank.com/drugs/DB17472
    ApprovedInvestigational

    Pirtobrutinib is a small molecule and a highly selective non-covalent inhibitor of Bruton’s tyrosine kinase (BTK). Its high selectivity has been associated with lower discontinuation rates due to adverse events and a lower incidence of a...

    Categories: Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 CYP1A2 Inhibitors
  5. Drug

    Vimseltinib

    go.drugbank.com/drugs/DB17520
    ApprovedInvestigational

    Vimseltinib is a small molecule kinase inhibitor targeting colony-stimulating factor 1 receptor (CSF1R). It is highly selective, with a >500-fold selectivity for CSF1R over its nearest off-target kinase. It is intended to provide a sa...

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  6. Drug

    Rilzabrutinib

    go.drugbank.com/drugs/DB17709
    ApprovedInvestigational

    Rilzabrutinib is an oral, reversible, covalent inhibitor of Bruton's tyrosine kinase that was approved by the FDA on August 29, 2025, for the treatment of persistent and chronic immune thrombocytopenia (ITP). ITP is an autoimmune disorde...

    Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 Substrates
  7. Drug

    Linafexor

    go.drugbank.com/drugs/DB18031
    Investigational

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  8. Drug

    Gunagratinib

    go.drugbank.com/drugs/DB18191
    Experimental

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  9. Drug

    Nerandomilast

    go.drugbank.com/drugs/DB18237
    ApprovedInvestigational

    Nerandomilast is a phosphodiesterase 4 (PDE4) inhibitor that preferentially inhibits the PDE4B subtype. It has one chiral center and is the R-stereoisomer. On October 7, 2025, nerandomilast was approved as the first new treatment for idi...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  10. Drug

    Sebetralstat

    go.drugbank.com/drugs/DB18305
    ApprovedInvestigational

    Hereditary angioedema (HAE) is a rare genetic disease that causes sudden, painful swelling episodes in various body locations that can be life-threatening, particularly when affecting the throat . Sebetralstat is the first and only oral ...

    Categories: Cytochrome P-450 Substrates, P-glycoprotein substrates